Nkarta Inc (NKTX NASDAQ) stock market data APIs
$2.4206
-0.09(-3.7%)
as of August 17, 2026
Try our APIs with
free plan!
Nkarta Inc Financial Data Overview
Price chart is built with
Anychart
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Prev. Close
2.4206
Open
2.33
High
2.4289
Low
2.3154
52 wk Range
1.7-3.72
Market Cap
174 M
Shares Outstanding
71 625 K
Revenue
385
EPS
-0.54
Beta
0.937
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Nkarta Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Nkarta Inc data using free add-ons & libraries
Get Nkarta Inc Fundamental Data
Nkarta Inc Fundamental data includes:
- Net Revenue: 385
- EBITDA: -113 441 000
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-10
- EPS/Forecast: -0.39
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Nkarta Inc News
New
Nkarta Posts Wider Loss In Q2; Provides Clinical Update On NKX019
(RTTNews) - Nkarta, Inc., (NKTX) a clinical-stage biotech company, posted its second quarter financial results, reflecting a wider net loss compared with the prior-year quarter, primarily attributed t...
Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development
Paris, France and New York, USA , July 23, 2026 (GLOBE NEWSWIRE) -- Alyssa Levin appointed to Board of Directors and as Chair of the Audit CommitteeClara Cambon-Thiebaud joins as VP, Regulatory Aff...
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
SOUTH SAN FRANCISCO, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to tre...
Nkarta GAAP EPS of -$0.37 in-line
* Nkarta press release [https://seekingalpha.com/pr/20512111-nkarta-reports-first-quarter-2026-financial-results-and-corporate-highlights] (NKTX [https://seekingalpha.com/symbol/NKTX]): Q1 GAAP EPS ...
Get Nkarta Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
